MedTech Innovator Vantage Non-Dilutive Funding Program: Up to $200K for Health Security Diagnostics and Devices

MedTech Innovator Vantage is a joint partnership between MedTech Innovator and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. Vantage is one of five specialized hubs in the BARDA Accelerator Network. Its Non-Dilutive Funding Program awards $50,000 to $200,000 for six-month, milestone-based projects that develop, evaluate, and validate diagnostic and medical device technologies for health security, preparedness, and response.

Deadline: Proposals are due October 15, 2026. Off-cycle applications for BARDA-aligned technologies are also accepted on a rolling basis.

Why This Opportunity Matters

Most early-stage medtech companies chase SBIR as their first federal dollar. Vantage is a faster, smaller entry point. A $50K to $200K award gives a startup proof-of-concept or validation data, a BARDA-aligned project record, and six months of project management and mentoring from subject matter experts. That record strengthens a later BARDA BAA, DRIVe, or SBIR application.

Key Facts at a Glance

• Sponsors: MedTech Innovator and BARDA (HHS), through the BARDA Accelerator Network
• Award size: $50,000 to $200,000
• Project length: 6 months, milestone-based
• Who can apply: Early-stage startups and university-backed projects
• Proposal window: September 1 to October 15, 2026
• Guided revisions: January 2027, with subject matter experts
• Award announcements: Anticipated March to April 2027
• Support included: Project management support and regular expert mentoring during the award
• Contact: vantage@medtechinnovator.org

Priority Technology Areas

Vantage funds diagnostic and medical device technologies that strengthen U.S. health security. Current priority areas include:

• Continuous patient monitoring: Platforms with advanced sensors, with emphasis on radiation injury and acute radiation syndrome
• Multiplexed point-of-care rapid tests: High-sensitivity tests, including botulinum toxin detection that distinguishes serotypes
• Deployable diagnostics: Low-cost tools for resource-limited settings
• Rapid triage diagnostics: Including low-throughput next-generation sequencing platforms for pathogen identification

What Is Out of Scope

• Oncology and chronic disease research
• Gain-of-function research involving pathogen manipulation

Is Your Company a Fit?

Vantage is a strong fit if your company:

• Is an early-stage startup or a university-backed spinout
• Is building a diagnostic, patient monitoring, or medical device technology with a clear health security use case
• Can define concrete, measurable milestones achievable in six months
• Plans to pursue larger BARDA or other federal funding after proof-of-concept

If your device targets cancer or a chronic disease without a preparedness or emergency response angle, other programs such as NIH SBIR are a better match.

How to Apply

1. Confirm alignment. Review BARDA's mission and the DRIVe target product profiles to map your technology to a stated health security need.
2. Define six-month milestones. Reviewers fund projects with specific development, evaluation, or validation outcomes that a $50K to $200K budget can deliver.
3. Submit by October 15, 2026. Proposals go to MedTech Innovator during the September 1 to October 15 window.
4. Revise with experts. Selected applicants refine proposals with subject matter experts in January 2027.
5. Award decision. Announcements are expected March to April 2027.

How BW&CO Helps

BW&CO has helped deep-tech, medtech, and biotech founders secure $350M+ in non-dilutive funding. We help you test fit against BARDA priorities, frame milestones reviewers trust, and plan the path from a Vantage award to BARDA BAA, DRIVe, and SBIR funding.

Frequently Asked Questions

What is the MedTech Innovator Vantage Non-Dilutive Funding Program?

It is a BARDA-aligned funding program run by MedTech Innovator that awards $50,000 to $200,000 for six-month projects developing, evaluating, and validating diagnostic and medical device technologies for health security.

When is the Vantage application deadline?

The 2026 proposal window runs September 1 to October 15, 2026. Off-cycle applications for BARDA-aligned technologies are accepted on a rolling basis.

Who is eligible to apply?

Early-stage startups and university-backed projects developing diagnostic or medical device technologies aligned with BARDA's health security mission.

Is Vantage funding dilutive?

No. Vantage awards are non-dilutive, so companies do not give up equity.

What technologies does Vantage prioritize?

Continuous patient monitoring for radiation injury, multiplexed point-of-care rapid tests such as botulinum toxin detection, low-cost deployable diagnostics, and rapid triage diagnostics including low-throughput NGS pathogen identification.

What is excluded from Vantage funding?

Oncology and chronic disease research, and gain-of-function research involving pathogen manipulation.

When are Vantage awards announced?

Selected applicants complete guided revisions in January 2027, and awards are anticipated in March to April 2027.

TRISH Catalyst Grants Program: NASA-Funded Space Health Awards for Companies and Researchers

The Translational Research Institute for Space Health (TRISH) funds disruptive, high-impact technologies and studies that protect astronaut health. TRISH is led by Baylor College of Medicine's Center for Space Medicine and funded through a NASA cooperative agreement with the NASA Human Research Program (HRP). The Catalyst Grants Program supports proof-of-concept projects and directed technology development. Tier 1 awards reach up to $150,000 over 12 months, and Tier 2 awards are $150,000 or more for larger projects.

Deadline: Rolling. Preliminary proposals are reviewed quarterly, and TRISH is accepting submissions through December 2026.

Why This Opportunity Matters

Many medtech problems in spaceflight mirror problems on Earth: remote monitoring, point-of-care diagnostics, blood clot prevention, behavioral health, and care with no specialist nearby. TRISH lets medtech and healthtech companies fund that work with NASA money, without the SBIR calendar. The two-page first step is light, U.S. companies are eligible, and a TRISH award builds a NASA track record that supports later NASA SBIR/STTR and HRP proposals.

Key Facts at a Glance

• Sponsor: TRISH at Baylor College of Medicine, funded by NASA's Human Research Program
• Tier 1: Under $150,000 total, up to 12 months
• Tier 2: $150,000 or more total, up to 18 months
• Budget rules: All direct and indirect costs count toward the total; minimum 10% cost share (cash or in-kind)
• Who can apply: U.S. institutions and companies with a documented base of ongoing R&D
• Submission: Rolling, with quarterly Step-1 reviews, through December 2026
• Notification: About 3 to 4 months after a Step-2 full proposal
• Contact: spacehealth-info@bcm.edu

What TRISH Funds

Catalyst projects must address critical human system risks on the NASA HRP roadmap, represent a unique, high-impact idea, and fall outside other open TRISH solicitations. Recent example topics include:

Ground-Based Research

• Countermeasures for internal jugular venous flow reversal
• Decompression sickness prevention
• Managing behavioral emergencies in remote environments
• Early detection of behavioral health decline

Flight Research

• Continuous characterization of venous flow during spaceflight
• Comparing venous thromboembolism countermeasures
• Evaluating post-flight motor control recovery

Is Your Company a Fit?

TRISH Catalyst is a strong fit if your company:

• Builds wearables, remote monitoring, point-of-care diagnostics, vascular, neuro, or behavioral health technology
• Can show how the technology reduces a specific spaceflight health risk
• Has ongoing R&D and preliminary data
• Can commit at least 10% cost share
• Wants a NASA relationship that extends into Earth-based clinical markets

How to Apply

1. Map to an HRP risk. Tie your technology to a named human system risk on the NASA Human Research Roadmap.
2. Submit a Step-1 preliminary proposal. Two pages maximum covering specific aims, deliverables, an implementation roadmap, TRISH alignment, and spaceflight health benefits. No institutional sign-off is required.
3. Prepare a Step-2 full proposal if invited. Tier 1 allows an 8-page project description and Tier 2 allows 15 pages, plus NASA SciENcv biosketches, Current and Pending Support, budget justification, a 2-page data management plan, and research security training certification.
4. Merit review. Reviewers score innovation, significance to NASA risk reduction, approach, and team, then assess budget, timeline, and data management.
5. Award. Decisions come about 3 to 4 months after Step-2, and start dates may shift with NASA budget availability.

How BW&CO Helps

BW&CO has helped deep-tech, medtech, and aerospace founders secure $350M+ in non-dilutive funding, including NASA awards. We help you frame your technology around NASA HRP risks, write a sharp two-page Step-1, and connect a TRISH award to NASA SBIR/STTR and Earth-based commercialization.

Frequently Asked Questions

What is the TRISH Catalyst Grants Program?

It is a NASA-funded program run by the Translational Research Institute for Space Health at Baylor College of Medicine that funds proof-of-concept projects and technology development addressing astronaut health risks.

Can companies apply for TRISH Catalyst grants?

Yes. U.S. institutions and companies are eligible if they have a documented base of ongoing research and development in science, healthcare, or technology.

How much funding does TRISH Catalyst provide?

Tier 1 awards are under $150,000 for up to 12 months. Tier 2 awards are $150,000 or more for up to 18 months. All direct and indirect costs count toward the total.

Is cost share required?

Yes. TRISH requires a minimum 10% cost share, which can be cash or in-kind.

What is the TRISH Catalyst deadline?

Submissions are rolling with quarterly Step-1 reviews, and TRISH is accepting applications through December 2026.

What does the Step-1 preliminary proposal require?

A two-page document covering specific aims, deliverables, an implementation roadmap, alignment with TRISH, and spaceflight health benefits. No institutional sign-off is needed.

How long does a TRISH award decision take?

Award notification is expected about 3 to 4 months after the Step-2 full proposal is submitted.